pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,644 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1837Endpoints1424Fierce Biotech743BioSpace733BioPharma Dive541raps242onclive165fda recalls116
therapy area
allOncology12702Rare Disease3291Immunology2967Cardiology2833Hematology2240Pulmonology2221Vaccines
  • CDC finds 10% of U.S. adults used GLP-1 drugs in 2025, 20% of them took compounded versions; Russia may seize foreign drug IP
    The Centers for Disease Control and Prevention reported that during July and August 2025 roughly one in ten U.S. adults said they had taken a GLP-1 medication at some point in the prior year. Amon…
    STAT · 9h agoNeutral↗ source
  • Democrats adopt "Medicare for More" as new health-care expansion message
    Democrats in the House have agreed on a new policy slogan, "Medicare for More," signaling a push to broaden health‑care coverage. The phrase is meant to set the agenda apart from the more ambitiou…
    STAT · 10h agoNeutral↗ source
← prev
page 2 of 146
next →
fda medwatch112
globenewswire health73
fda press59
1822
Psychiatry & CNS1225
Ophthalmology1125
Endocrinology & Metabolism794
Pain784
Nephrology767
New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
BioPharma Dive · 13h agoPositive↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 14h agoNeutral↗ source
  • STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
    A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.
    STAT · 10h agoRegulatoryNeutral↗ source
  • Physician burnout persists as hospitals push self-care instead of systemic fixes
    In a new STAT+ column, former ENT surgeon Frances Mei Hardin reflects on the growing crisis of physician burnout and the limited impact of hospital‑mandated wellness programs. Hardin shares a pers…
    STAT · 14h agoNegative↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 22h agoNeutral↗ source
  • FDA proposes new classification that formally recognizes NAC as a dietary ingredient, ending its legal gray area
    The FDA announced a proposed rule that would create a new regulatory category for N-acetyl-L-cysteine (NAC), a product long sold as a dietary supplement. Under the proposal, NAC would be classifie…
    STAT · 4h agoRegulatoryPositive↗ source
  • Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program dropped
    Aclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…
    Fierce Biotech · 15h agoNegative readoutNegative↗ source
  • Health-care providers turn to lawsuits over unpaid services as insurance costs squeeze paychecks
    Health-care providers are increasingly filing lawsuits to collect unpaid fees, according to a STAT+ newsletter that cites cases such as an air-ambulance company suing a plumber and a claim involvin…
    STAT · 6h agoNegative↗ source
  • VC John Doerr praises Tom Health AI tool as promising solution for primary care
    Venture capitalist John Doerr highlighted a new artificial-intelligence platform called Tom Health, noting its potential impact on primary-care delivery. Doerr, whose brother's name inspired the c…
    STAT · 12h agoPositive↗ source
  • Kennedy's MAHA Initiative Gains Momentum with Stephen Miller as White House Chief of Staff
    Stephen Miller's recent appointment as White House chief of staff has been described as a catalyst for the health secretary's MAHA agenda. The move appears to have energized the initiative, accordi…
    STAT · 14h agoPositive↗ source
  • Proposal to start medical school after Step 1 exam to cut debt and boost diversity
    The authors, bioethicists at SUNY Upstate Medical University, argue that medical education should be split into two distinct phases. The first phase would cover the pre‑clinical sciences that are t…
    STAT · 14h agoPositive↗ source
  • STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
    The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
    STAT · 1d ago↗ source
  • Medline recalls all brand beds, rails, mattresses and accessories over fire and entrapment risk
    Medline announced a recall of its entire line of Medline Brand beds, rails, mattresses and related accessories in the United States and Canada. The recall, launched on October 14, 2026, cites a po…
    fda recalls · 3d agoCRLNegative↗ source
  • FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer
    The U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…
    Fierce Biotech · 3d agoRegulatoryNegative↗ source
  • Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapy
    Novo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
    BioPharma Dive · 3d agoApprovalPositive↗ source
  • Takeda narcolepsy pill receives DEA clearance as Oura-Lilly deal raises conflict concerns and Pfizer exits Canadian Premarin market
    Takeda announced that its experimental narcolepsy medication has been cleared by the U.S. Drug Enforcement Administration, marking the first regulatory nod for a therapy aimed at treating excessive…
    STAT · 3d agoRegulatoryPositive↗ source
  • Neuroscience startups attract $450M in recent funding, Oyster Therapeutics secures $60M Series A
    Venture capital activity around neuroscience has picked up again, with five neurology-focused startups collectively raising about $450 million in the past few weeks. Data from BioPharma Dive show…
    BioPharma Dive · 3d agoDealPositive↗ source
  • Windward Bio raises $225 million in IPO to fund Chinese-sourced respiratory drug program
    Windward Bio, backed by Sanofi, completed its initial public offering at the $225 million target, selling 10.3 million shares at $17 each. The proceeds will be used to advance two respiratory drug…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitor
    Windward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
    BioPharma Dive · 3d agoDealPositive↗ source
  • HHS to allocate up to $4.9 million for ibogaine research targeting PTSD
    The U.S. Department of Health and Human Services announced it will provide up to $4.9 million to support research on ibogaine, a psychedelic compound. The funding is intended to explore ibogaine’s…
    STAT · 3d agoRegulatoryNeutral↗ source
  • Setbacks in two heart disease trials raise questions about future cardiovascular drug research
    A recent episode of The Readout LOUD highlighted the disappointing results of two high-profile heart disease drugs, noting that both failed to demonstrate benefit in recent studies. The failures w…
    STAT · 3d agoNegative readoutNegative↗ source
  • Gate Bioscience eyes clinic trials with molecular gate drugs, backed by expanded $870M Lilly partnership
    Gate Bioscience is developing small-molecule drugs that block the Sec61 channel, preventing disease-causing proteins from entering cells and leading to their degradation. The company's first discl…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Charles River acquires two Frontage bioanalysis labs in Pennsylvania for $470 million
    Charles River Laboratories announced it has purchased two laboratory sites from Tigermed’s Frontage in Exton, Pennsylvania, paying $470 million upfront. The labs together span about 150,000 square…
    Fierce Biotech · 3d agoDealPositive↗ source